Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer

Fig. 3

Overall frequency of TRAEs leading to discontinuation according to PD-1/PD-L1 inhibitor type and PD-L1 expression. Abbreviations: AEs, adverse events; FAEs, fatal adverse events; PD-L1, programmed cell death protein ligand-1; SAEs, serious adverse events; TRAEs, treatment-related adverse events. ns indicates nonsignificant differences (P > 0.05), and * indicates P < 0.05

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us